Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2407
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer ; volume:16 ; number:1 ; day:6 ; month:6 ; year:2016 ; pages:1-9 ; date:12.2016
BMC cancer ; 16, Heft 1 (6.6.2016), 1-9, 12.2016
- Urheber
-
Tominaga, Tetsuro
- Beteiligte Personen und Organisationen
-
Tsuchiya, Tomoshi
Mochinaga, Koji
Arai, Junichi
Yamasaki, Naoya
Matsumoto, Keitaro
Miyazaki, Takuro
Nagasaki, Toshiya
Nanashima, Atsushi
Tsukamoto, Kazuhiro
Nagayasu, Takeshi
SpringerLink (Online service)
- DOI
-
10.1186/s12885-016-2392-0
- URN
-
urn:nbn:de:1111-20160608832
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tominaga, Tetsuro
- Tsuchiya, Tomoshi
- Mochinaga, Koji
- Arai, Junichi
- Yamasaki, Naoya
- Matsumoto, Keitaro
- Miyazaki, Takuro
- Nagasaki, Toshiya
- Nanashima, Atsushi
- Tsukamoto, Kazuhiro
- Nagayasu, Takeshi
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Proinflammatory cytokines regulate epidermal stem cells in wound epithelialization
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen
Proinflammatory cytokines regulate epidermal stem cells in wound epithelialization
Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non–small-cell lung cancer patients: a prospective observational study
Icotinib is as efficacious as gefitinib for brain metastasis of EGFR mutated non-small-cell lung cancer
Efficacy of osimertinib in epidermal growth factor receptor-mutated non-small-cell lung cancer patients with pleural effusion
Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study
Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC
Genetic diagnostic features after failure of initial treatment with epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors among non-small-cell lung cancer patients harboring EGFR mutations
Exosomes: a new perspective in EGFR-mutated lung cancer
Fatty acid synthase mediates EGFR palmitoylation in EGFR mutated non‐small cell lung cancer
Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations
Representativeness of Phase III Trial for Osimertinib in Pretreated Advanced EGFR-Mutated Non-small-cell Lung Cancer Patients and Treatment Outcomes in Clinical Practice
Veränderung des Epidermal Growth Factor Receptors (EGFR) bei Sarkomen